Javascript must be enabled to continue!
QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA
View through CrossRef
Abstract
OBJECTIVE
Tumour-treating fields (TTFields) have changed the first-line clinical practice of glioblastoma worldwide due to their promising therapeutic efficacy. The aim of this study was to investigate the clinical efficacy of TTFields therapy for HGG in Nanfang Hospital, China. In 2023 ASNO we reported PFS.Now we reporte update about OS from our single center study.
METHODS
From January 2019 to December 2022, a total of 25 patients with newly diagnosed HGG (ndHGG) treated with TTFields were retrospectively included in our study. Among these patients, 9 patients received concurrent radiochemotherapy in combination with TTFields and 16 patients received non-concurrent chemoradiotherapy in combination with TTFields. The primary endpoint of the study was mPFS and mOS (Kaplan-Meier method used to estimate PFS and OS survival curves). Secondary endpoint was the influences about KPS score in PFS and OS.
RESULTS
The 25 ndHGG patients treated with TTFields included nine males and sixteen females with a mean age of 47.1 years (12-68). Gross total resection (GTR) was performed in eighteen patients. Twenty-one patients were IDH wild type, eleven patients showed methylation of the MGMT promoter. Followed up until January 2024, the median PFS was 13.3 months [95% CI: 11.33-15.2] with TTFields combined and 4.0 months (95% CI, 3.8-4.4) without TTFields treatment in EF-14.Median OS was 26.53 months [95% CI:19.47-33.57] with TTFields and 16.0 months (95% CI, 3.8-4.4) control in EF-14. In the KPS stratification, OS was 27.5 months (95% CI: 22.95-32.1) vs 4.3 months (95% CI: 0-11.2), p=0.0001. The OS of patients with concurrent chemoradiotherapy combined with TTFields vs. without concurrent chemoradiotherapy combined with TTFields was 26.5 months (95% CI: 24.33-28.7) vs 21.2 (95% CI: 3.1-39.3) months, p=0.59.
CONCLUSIONS
TTFields therapy is an effective treatment for HGG. In this study the addition of TTFields resulted in a statistically significant improvement in PFS and OS.
Oxford University Press (OUP)
Title: QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA
Description:
Abstract
OBJECTIVE
Tumour-treating fields (TTFields) have changed the first-line clinical practice of glioblastoma worldwide due to their promising therapeutic efficacy.
The aim of this study was to investigate the clinical efficacy of TTFields therapy for HGG in Nanfang Hospital, China.
In 2023 ASNO we reported PFS.
Now we reporte update about OS from our single center study.
METHODS
From January 2019 to December 2022, a total of 25 patients with newly diagnosed HGG (ndHGG) treated with TTFields were retrospectively included in our study.
Among these patients, 9 patients received concurrent radiochemotherapy in combination with TTFields and 16 patients received non-concurrent chemoradiotherapy in combination with TTFields.
The primary endpoint of the study was mPFS and mOS (Kaplan-Meier method used to estimate PFS and OS survival curves).
Secondary endpoint was the influences about KPS score in PFS and OS.
RESULTS
The 25 ndHGG patients treated with TTFields included nine males and sixteen females with a mean age of 47.
1 years (12-68).
Gross total resection (GTR) was performed in eighteen patients.
Twenty-one patients were IDH wild type, eleven patients showed methylation of the MGMT promoter.
Followed up until January 2024, the median PFS was 13.
3 months [95% CI: 11.
33-15.
2] with TTFields combined and 4.
0 months (95% CI, 3.
8-4.
4) without TTFields treatment in EF-14.
Median OS was 26.
53 months [95% CI:19.
47-33.
57] with TTFields and 16.
0 months (95% CI, 3.
8-4.
4) control in EF-14.
In the KPS stratification, OS was 27.
5 months (95% CI: 22.
95-32.
1) vs 4.
3 months (95% CI: 0-11.
2), p=0.
0001.
The OS of patients with concurrent chemoradiotherapy combined with TTFields vs.
without concurrent chemoradiotherapy combined with TTFields was 26.
5 months (95% CI: 24.
33-28.
7) vs 21.
2 (95% CI: 3.
1-39.
3) months, p=0.
59.
CONCLUSIONS
TTFields therapy is an effective treatment for HGG.
In this study the addition of TTFields resulted in a statistically significant improvement in PFS and OS.
Related Results
Abstract 2094: Prostaglandin E receptor 3 mediates resistance to tumor treating fields in glioblastoma cells
Abstract 2094: Prostaglandin E receptor 3 mediates resistance to tumor treating fields in glioblastoma cells
Abstract
Glioblastoma (GBM) is the most common and deadliest malignant brain cancer in adults despite surgery and aggressive chemoradiotherapy. Tumor Treating Fields...
Abstract 2018: Tumor treating fields (TTFields) disrupt cancer cell invasion by impacting cell-ECM traction forces
Abstract 2018: Tumor treating fields (TTFields) disrupt cancer cell invasion by impacting cell-ECM traction forces
Abstract
Introduction: Tumor Treating Fields (TTFields) are an anti-cancer treatment that use low intensity, alternating electric fields. Anti-mitotic treatment effe...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Forschungsfortschritt zum Mechanismus der durch TTFields induzierten Antitumor-Immunantwort
Forschungsfortschritt zum Mechanismus der durch TTFields induzierten Antitumor-Immunantwort
Tumortherapiefelder (TTFields), eine biophysikalische Therapietechnologie, die elektrische Wechselfelder zur Hemmung der Tumorproliferation einsetzt, wurden von der US-amerikanisch...
Therapeutic Potential of Tumor Treating Fields for Malignant Brain Tumors
Therapeutic Potential of Tumor Treating Fields for Malignant Brain Tumors
Background Malignant brain tumors are among the most threatening
diseases of the central nervous system, and despite increasingly updated
treatments, the prognosis has not been imp...
Effects of craniectomy defect on tumor-treating fields
Effects of craniectomy defect on tumor-treating fields
Abstract
Background
Tumor-treating fields (TTFields) are alternating electric fields approved for the treatment of glioblastoma....
Comprehensive analysis of Histone deacetylases genes in the prognosis and immune infiltration of glioma patients
Comprehensive analysis of Histone deacetylases genes in the prognosis and immune infiltration of glioma patients
Abstract
The occurrence and development of tumors are closely related to histone deacetylases (HDACs). However, the overall biology and prognosis are still unknown ...
Induction of prostaglandin E2 synthesis and microsomal prostaglandin E synthase–1 expression in murine microglia by glioma-derived soluble factors
Induction of prostaglandin E2 synthesis and microsomal prostaglandin E synthase–1 expression in murine microglia by glioma-derived soluble factors
Object
Microglia are one of the members of monocyte/macrophage lineage in the central nervous system (CNS) and exist as ramified microglia in a normal resting state, but they are a...

